Nutshell Therapeutics
PrivateLast Round
Series A
Extension
Mar 14, 2022
Total Funding Raised
$60M
Company Overview
Nutshell Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A Extension round in March 2022.
Nutshell Therapeutics is a biotechnology company that develops small molecule drugs for challenging targets using its proprietary AI-driven allosteric drug discovery platform, AlloStar.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nutshell Therapeutics Comparables
Compare Nutshell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atavistik Bio | 85% | |
| HotSpot Therapeutics | 82% | |
| UCDOM BioTech (Shanghai) Co., Ltd. | 79% |
For institutional investors. Book with your work email.
Nutshell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 14, 2022 | ||||
| Series A | Jan 13, 2022 | ||||
| VC Round | Sep 6, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nutshell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Baidu Ventures | Series A |
| Northern Light Venture Capital | Series A |
| MPC | Series A |
| Source Code Capital | Series A |
| Genesis Capital | Series A Extension |
| Kunlun Capital | Series A |
| Straylight Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 14, 2022
$40M round led by Genesis Capital.
For institutional investors. Book with your work email.
Nutshell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nutshell Therapeutics's valuation, stock price, and market status.
Is Nutshell Therapeutics a public or private company?
Nutshell Therapeutics is a private company.
What is the current stock price of Nutshell Therapeutics?
Nutshell Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nutshell Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nutshell Therapeutics worth (valuation)?
Valuation information for Nutshell Therapeutics is not publicly available.
Can I buy Nutshell Therapeutics stock?
Nutshell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nutshell Therapeutics's last funding round?
Nutshell Therapeutics's most recent funding round was Series A Extension on March 14, 2022.
Who are the main investors in Nutshell Therapeutics?
Key investors in Nutshell Therapeutics include MPC, Genesis Capital, Straylight Capital.
Will Nutshell Therapeutics IPO soon?
No public IPO plans have been announced for Nutshell Therapeutics.
How can I track Nutshell Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nutshell Therapeutics's shares on secondary markets.